In adults with AMI who are at risk for HF, empagliflozin did not reduce a composite of first HF hospitalization or all-cause death at 18 mo

Ann Intern Med. 2024 Jul;177(7):JC74. doi: 10.7326/ANNALS-24-00809-JC. Epub 2024 Jul 2.

Authors

Stormy Keppel¹, Steven Borzak¹

Affiliation

¹ University of Miami Miller School of Medicine, JFK Campus, Atlantis, Florida, USA (S.K., S.B.).

PMID: 38950404
DOI: 10.7326/ANNALS-24-00809-JC

Abstract

Butler J, Jones WS, Udell JA, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390:1455-1466. 38587237.

Publication types

Comment

MeSH terms

Aged
Benzhydryl Compounds* / therapeutic use
Cause of Death
Female
Glucosides* / therapeutic use
Heart Failure* / drug therapy
Heart Failure* / mortality
Hospitalization*
Humans
Male
Middle Aged
Myocardial Infarction* / mortality
Myocardial Infarction* / prevention & control
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Benzhydryl Compounds
empagliflozin
Glucosides
Sodium-Glucose Transporter 2 Inhibitors